Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!

Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!

Abstract Objective Herd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the...

Full description

Bibliographic Details
Main Authors: Amandine Mveang Nzoghe, Marielle Leboueny, Eliane Kuissi Kamgaing, Anicet Christel Maloupazoa Siawaya, Eliode Cyrien Bongho, Ofilia Mvoundza Ndjindji, Guy-Stephan Padzys, Bénédicte Ndeboko, Simon Ategbo, Joel Fleury Djoba Siawaya
Format: Article
Language:English
Published: BMC 2021-04-01
Series:BMC Research Notes
Subjects:
SARS-CoV-2
Antibodies
Infants
Children
Adults
Online Access:https://doi.org/10.1186/s13104-021-05570-3

Internet

https://doi.org/10.1186/s13104-021-05570-3

Similar Items